Stakeholders' experiences with a clinician-led access programme linking evidence generation and reimbursement for precision cancer treatments: the drug access protocol in the Netherlands.

ABSTRACT:

Background and purpose

In the current landscape of tumour-agnostic oncology drugs receiving European Medicines Agency (EMA) authorisation, Health Technology Assessment (HTA) bodies face challenges in assessing these innovative drugs. Due to these products' non-randomised, single-arm nature, uncertainty exists regarding their real-world benefit. In the Netherlands, the Drug Access Protocol (DAP), a programme developed by oncologists, insurers and the healthcare public institute, aims to provide an innovative solution to address this uncertainty. This study aims to investigate the key characteristics, enablers and challenges of the programme by exploring stakeholders' perceptions. Patient/material and methods: A qualitative, semi-structured interview study was conducted. A supporting

SUBMITTER: Leopold C 

PROVIDER: S-EPMC12816994 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature